Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Heart and Lung Institute Nutricia Research Foundation (formerly Ovita Nutricia Research Foundation) |
---|---|
Information provided by: | National Heart and Lung Institute |
ClinicalTrials.gov Identifier: | NCT00654719 |
The purpose of this study was to determine the effects of a high caloric drink on weight and several other clinical markers including quality of life in patients with unintentional weight loss (cachexia) due to chronic heart failure.
Condition | Intervention | Phase |
---|---|---|
Chronic Heart Failure Cardiac Cachexia |
Dietary Supplement: NutriDrink Dietary Supplement: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment |
Official Title: | The Influence of Enteral Nutrition on Functional Status and Inflammatory Activation in Patients With Congestive Heart Failure and Cardiac Cachexia. |
Enrollment: | 29 |
Study Start Date: | April 2001 |
Study Completion Date: | February 2002 |
Primary Completion Date: | February 2002 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
NutriDrink: Active Comparator
Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
|
Dietary Supplement: NutriDrink
Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
|
Placebo: Placebo Comparator |
Dietary Supplement: Placebo
Nutritional supplementation containing only 12 kcal/day
|
Cardiac cachexia has been shown to be powerful independent predictor of mortality in patients with congestive heart failure (CHF). Unlike starvation, cachectic CHF patients present with a decrease of muscles and/or fat tissue. This probably depends, at least in part, on the level of inflammatory activation. Theoretically, it seems clear that nutritional status has to be improved in cardiac cachexia. It has been suggested that inflammatory activation in CHF may be due to endotoxin translocation through the edematous gut wall. Elevated endotoxin levels have been found in patients with acutely decompensated CHF, but these levels normalized with diuretic treatment. This finding may be of utmost importance. From one side it underscores the need for aggressive diuretic treatment to prevent translocation, from another side however, it suggests potential area for enteral treatment. Enteral route of nutrition may be highly beneficial by diminishing bacterial translocation from guts and/or endotoxin transfer, finally resulting in lower inflammatory activation Numerous experimental studies display that enteral feeding reduces bacterial translocation, endotoxin absorption and positively modulates function of local immune tissue.
A search of the literature shows that very little is known about the effectiveness of nutritional support on functional performance in cachectic CHF patients and actually no reports concern the influence of enteral feeding on immune activation of cachectic CHF patients. Recent information of some links existing between leptin, which is increased in CHF, and inflammatory activation in this syndrome speculate on a functional role of leptin in immune activation in CHF. As leptin is one of the most important hormones in the regulation of body energy metabolism, we think it is reasonable to look also into enteral feeding -induced changes of leptin and concomitant fluctuations of plasma cytokines.
During the last 12 months we have been using nutritional support in cachectic patients with CHF as an adjunct to standard therapy. We were surprised by a significant functional improvement that we observed in many instances. As most of these patients were subjected to aggressive multi-drug diuretic therapy as well, it was impossible to appreciate the role of enteral nutrition in this respect. We think, these observations are worth verification in more controlled prospective studies.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum | |
Berlin, Germany, 13353 | |
Poland | |
Silesian Center for Heart Diseases | |
Zabrze, Poland, 41-800 |
Responsible Party: | Nutricia Research Foundation ( Iwona Wójcicka-Bartłomiejczyk, director ) |
Study ID Numbers: | 372/2000 |
Study First Received: | April 3, 2008 |
Last Updated: | April 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00654719 History of Changes |
Health Authority: | Poland: National Monitoring Centre for Clinical Trials - Ministry of Health |
Heart failure cachexia |
Body Weight Signs and Symptoms Heart Failure Heart Diseases |
Weight Loss Body Weight Changes Cachexia Emaciation |
Body Weight Signs and Symptoms Heart Failure Heart Diseases Weight Loss |
Body Weight Changes Cachexia Cardiovascular Diseases Emaciation |